Endorphin Global

Tirzepatide

Dual GIP/GLP-1 agonist clinically shown to accelerate medical weight loss, improve glycemic control, and support sustainable body recomposition.

Rapid, clinically proven weight loss
Appetite regulation and satiety support
Improved insulin sensitivity and metabolic health

New Patients Only Plans

Results

Weight Loss

15-20% total body weight in clinical trials

Reduced visceral fat

Improved body composition

Metabolic

Improved glycemic control

Reduced HbA1c levels

Better lipid profiles

Administration

Starting dosage: 2.5 mg once weekly

Maintainance dosage: 5 mg, 10 mg, 15 mg

Injection Site: Abdomen, thigh, or upper arm

Side Effects

Common ( >10% ):

Nausea

Diarrhea

Decreased appetite

Vomiting

Less Common ( 5-10% ):

Constipation

Dyspepsia

Fatigue

Abdominal pain

Preacaution

History of medullary thyroid carcinoma

Multiple Endocrine Neoplasia syndrome type 2

Pancreatitis

Gallbladder disease

Disclaimer

The content provided is for educational and informational purposes only. It is not medical advice, nor should it be used as a substitute for professional diagnosis or treatment. Always consult a licensed physician or other qualified healthcare provider with any questions regarding your health, medical condition, or treatment options. Do not ignore or delay seeking professional medical advice because of something you have read, heard, or accessed through this platform. Any reliance on the information provided is at your own risk.